This proposal examines the regulatory effects of microbe- and host-derived activation factors on the innate immune system in an experimental model of human disease. Human Sleeping Sickness is a fatal disease characterized by extensive functional, histological and pathological changes in the lymphoid tissues of Trypanosoma spp. infected hosts. Among these changes is an increase in the numbers and activation state of cells of the mononuclear phagocyte system. Macrophage activation during infection occurs in response to molecules released by the parasite as well as to IFN-y produced by T cells in response to parasite antigens. These activation events occur episodically throughout infection, associated with waves of parasite growth and immune destruction; thus trypanosome infections represent a natural model in which the macrophage component of the innate immune system is exposed in a recurrent manner to microbial factors (""""""""danger"""""""" signals) and to host cytokines. We present evidence that the two factors produce distinct patterns of macrophage activation during infection, and that the balance or interaction of the different activation signals may determine the progression of disease and outcome of infection. Since the macrophage activation response is based on distinct membrane-associated signaling events, and since macrophage activation is intimately linked to host protection, an effort to understand the molecular basis for macrophage activation is clearly an important scientific step towards understanding the host-parasite relationship and the concept of macrophage co-activation during microbial infection. Therefore, this proposal examines basic elements of cell biology and molecular signaling to dissect the macrophage activation response in African trypanosomiasis. The ultimate goal is to uncover novel regulatory mechanisms associated with macrophage activation that can be exploited to provide greater resistance to disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI051421-05
Application #
7067148
Study Section
Special Emphasis Panel (ZRG1-SSS-F (01))
Program Officer
Wali, Tonu M
Project Start
2002-06-15
Project End
2008-05-31
Budget Start
2006-06-01
Budget End
2008-05-31
Support Year
5
Fiscal Year
2006
Total Cost
$177,602
Indirect Cost
Name
University of Wisconsin Madison
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Inverso, Jill A; Uphoff, Timothy S; Johnson, Scott C et al. (2010) Biological variation among african trypanosomes: I. Clonal expression of virulence is not linked to the variant surface glycoprotein or the variant surface glycoprotein gene telomeric expression site. DNA Cell Biol 29:215-27
Dagenais, Taylor R; Freeman, Bailey E; Demick, Karen P et al. (2009) Processing and presentation of variant surface glycoprotein molecules to T cells in African trypanosomiasis. J Immunol 183:3344-55
Dagenais, Taylor R; Demick, Karen P; Bangs, James D et al. (2009) T-cell responses to the trypanosome variant surface glycoprotein are not limited to hypervariable subregions. Infect Immun 77:141-51
Lopez, Rebecca; Demick, Karen P; Mansfield, John M et al. (2008) Type I IFNs play a role in early resistance, but subsequent susceptibility, to the African trypanosomes. J Immunol 181:4908-17
Harris, Tajie H; Mansfield, John M; Paulnock, Donna M (2007) CpG oligodeoxynucleotide treatment enhances innate resistance and acquired immunity to African trypanosomes. Infect Immun 75:2366-73
Leppert, Brian J; Mansfield, John M; Paulnock, Donna M (2007) The soluble variant surface glycoprotein of African trypanosomes is recognized by a macrophage scavenger receptor and induces I kappa B alpha degradation independently of TRAF6-mediated TLR signaling. J Immunol 179:548-56
Harris, Tajie H; Cooney, Nicole M; Mansfield, John M et al. (2006) Signal transduction, gene transcription, and cytokine production triggered in macrophages by exposure to trypanosome DNA. Infect Immun 74:4530-7